CLICK HERE AND READ THEM PLUS OTHERS WE WILL BE POSTING!! LOTS OF EXCITING NEWS FOR MSers!!:

www.MSnewsChannel.com


ECTRIMS: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -
ECTRIMS Congress 2013: New TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
ECTRIMS Congress 2013: SLIDE SHOW: WHY GREY MATTERS...BRAIN ATROPHY IN MS: WHAT ARE ITS CONSEQUENCES?

ECTRIMS Congress 2013: Higher Vitamin D Levels Linked to Less MS Activity
ECTRIMS Congress 2013: African Americans With MS at More Visual Risk

ECTRIMS Congress 2013: Biogen covers all bases for personalised approach to MS

Halting MS to Be Focus at ECTRIMS Congress 2013

ECTRIMS Congress 2013:  New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis

ECTRIMS Congress 2013: Scientists from ENDECE Neural presented preclinical data today showing that the company’s lead compound, NDC-1308, addresses one of the root causes of multiple sclerosis (MS) by significantly inducing remyelination in nerves that have been damaged by MS

ECTRIMS Congress 2013: Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

ECTRIMS Congress 2013: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -

ECTRIMS Congress 2013: Biogen Idec's new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least 4 years with no new safety problems

ECTRIMS Congress 2013: COPAXONE (Glatiramer acetate)  20 mg daily associated with stable disease activity over the course of the twenty-year study presented at the 29th ECTRIMS congress

ECTRIMS Congress 2013: Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates

ECTRIMS Congress 2013: GILENYA REDUCES MS RELAPSE RATES COMPARED TO INTERFERONS OR GLATIRAMER ACETATE

ECTRIMS Congress 2013: NOVARTIS, SANOFI AND BIOGEN TOUT NEW MS DRUG RESEARCH
 
ECTRIMS Congress 2013: "BRAIN ATROPHY CAN PRECEDE MS SYMPTOM"

ECTRIMS Congress 2013: "EARLY, STEADY MS TREATMENT CUTS PROGRESSION RISK" (Day 1 ECTRIMS News)

ECTRIMS Congress 2013: Vitamin D for All to Prevent MS? Vitamin D for all MSers?

Labels: Aubagio, ECTRIMS CONGRESS 2013, Gilenya, TECFIDERA, Tysabri, Vitamin D

Director, Neurology Clinical Research Professor, Department of Neurology UNIVERSITY OF COLORADO Co-Director, Rocky Mountain MS Center at Anschutz Medical Director, ROCKY MOUNTAIN MS CENTER

ECTRIMS Congress 2013:  AMSTERDAM -- A low-dose regimen of the leukemia drug alemtuzumab (Lemtrada) slashed annualized relapse rates in patients with newly diagnosed multiple sclerosis in a head-to-head trial against interferon-beta-1a (Rebif), a researcher reported here.

Patients taking alemtuzumab -- first sold under the brand name Campath for treating B-cell chronic lymphocytic leukemia -- had a mean annualized relapse rate of 0.18 during a two-year, phase III trial, compared with 0.39 for patients receiving the standard regimen of interferon. But another neurologist not involved with the study suggested that the drug's safety profile remains a major concern.

Timothy Vollmer, MD, of the University of Colorado in Denver, said the extreme duration of alemtuzumab's effects was itself a potential problem.

"[It] induces long-term if not permanent changes in immunoregulation; it also induces significant generalized immune suppression and disturbance of immunoregulatory circuits," he observed.

As a result, said Vollmer, "once you treat a patient, you can't take it back. Those patients are then at risk for infections and for development of autoimmune disease."

He added that he considered these risks more worrisome than the potential for progressive multifocal leukoencephalopathy with natalizumab (Tysabri).

Coles reported findings from the 581-patient trial, dubbed CARE-MS I, during a late-breaking news session at the joint meeting of the European and Americas Committees for Treatment and Research in Multiple Sclerosis.

Patients in the study had disease duration of no more than five years and EDSS disability scores of 3 or less, but had active disease on the basis of  relapses during the previous two years. Patients who had received disease-modifying therapies previously were excluded.

The difference in relapse rates meant the cancer drug met one of two primary endpoints in the study, which was intended to demonstrate alemtuzumab's superiority to one of the mainstays of first-line MS therapy.
Read more »

Labels: ECTRIMS CONGRESS 2013, Lemtrada, Rebif, Tysabri